Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome)

被引：91
作者：
Bresler S.C. [1 ,2 ]
Padwa B.L. [3 ,4 ]
Granter S.R. [1 ,2 ]
机构：
[1] Department of Pathology, Brigham and Women’s Hospital, 75 Francis St., Boston, 02115, MA
[2] Harvard Medical School, Boston, MA
[3] Department of Plastic and Oral Surgery, Boston Children’s Hospital, Boston, MA
[4] Harvard School of Dental Medicine, Boston, MA
来源：
Head and Neck Pathology | 2016年 / 10卷 / 2期
关键词：
Basal cell nevus syndrome; Gorlin syndrome; Keratocystic odontogenic tumor; Nevoid basal cell carcinoma syndrome; PTCH1; SMO; SUFU; Vismodegib;
D O I：
10.1007/s12105-016-0706-9
中图分类号：
学科分类号：
摘要：
Nevoid basal cell carcinoma syndrome, or basal cell nevus syndrome (Gorlin syndrome), is a rare autosomal dominantly inherited disorder that is characterized by development of basal cell carcinomas from a young age. Other distinguishing clinical features are seen in a majority of patients, and include keratocystic odontogenic tumors (formerly odontogenic keratocysts) as well as dyskeratotic palmar and plantar pitting. A range of skeletal and other developmental abnormalities are also often seen. The disorder is caused by defects in hedgehog signaling which result in constitutive pathway activity and tumor cell proliferation. As sporadic basal cell carcinomas also commonly harbor hedgehog pathway aberrations, therapeutic agents targeting key signaling constituents have been developed and tested against advanced sporadically occurring tumors or syndromic disease, leading in 2013 to FDA approval of the first hedgehog pathway-targeted small molecule, vismodegib. The elucidation of the molecular pathogenesis of nevoid basal cell carcinoma syndrome has resulted in further understanding of the most common human malignancy. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：119 / 124
页数：5
相关论文
共 33 条
[1]  
Howell B., Caro M., The basal-cell nevus, Arch Dermatol, 79, pp. 67-80, (1959)
[2]  
Gorlin R., Goltz R., Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome, N Engl J Med, 5, pp. 908-912, (1960)
[3]  
Kimonis V.E., Goldstein A.M., Pastakia B., Yang M.L., Kase R., Digiovanna J.J., Et al., Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome, Am J Med Genet, 69, pp. 299-308, (1997)
[4]  
Anderson D.E., Taylor W.B., Falls H.F., Davidson R.T., The nevoid basal cell carcinoma syndrome, Am J Hum Genet, 19, pp. 12-22, (1967)
[5]  
Shanley S., Ratcliffe J., Hockey A., Haan E., Oley C., Ravine D., Et al., Nevoid basal cell carcinoma syndrome: review of 118 affected individuals, Am J Med Genet, 50, pp. 282-290, (1994)
[6]  
Johnson R.L., Rothman A.L., Xie J., Goodrich L.V., Bare J.W., Bonifas J.M., Et al., Human homolog of patched, a candidate gene for the basal cell nevus syndrome, Science, 272, pp. 1668-1671, (1996)
[7]  
Klein R.D., Dykas D.J., Bale A.E., Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory, Genet Med, 7, pp. 611-619, (2005)
[8]  
Gailani M.R., Stahle-Backdahl M., Leffell D.J., Glynn M., Zaphiropoulos P.G., Pressman C., Et al., The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas, Nat Genet, 14, pp. 78-81, (1996)
[9]  
Gailani M.R., Bale S.J., Leffell D.J., DiGiovanna J.J., Peck G.L., Poliak S., Et al., Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9, Cell, 69, pp. 111-117, (1992)
[10]  
Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., Et al., Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome, Cell, 85, pp. 841-851, (1996)
1234